Leukemia Clinical Trials

A listing of Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 731 clinical trials
Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)

This research study uses special blood cells called multiple tumor-associated antigen (TAA)-specific T cells (a new experimental therapy) to treat patients with acute myeloid leukemia (AML) or

chromosome abnormality
cancer
lymphoma
residual tumor
minimal residual disease
  • 54 views
  • 15 Jun, 2022
  • 2 locations
Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes

The study is a Phase II clinical trial. Patients will receive intensity modulated total marrow irradiation (TMI) at a dose of 9 Gy with standard myeloablative fludarabine/ i.v. targeted busulfan (FluBu) conditioning prior to allogeneic hematopoietic stem cell transplant (HSCT).

tacrolimus
refractory acute myeloid leukemia (aml)
remission
cytopenia
busulfan
  • 6 views
  • 30 Jun, 2022
  • 1 location
PRGN-3006 Adoptive Cellular Therapy for Relapsed or Refractory AML or Higher Risk MDS

chimeric antigen receptor (CAR) T cells), in adult patients with relapsed or recurred acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS). Autologous CAR T cells are modified immune

refractory acute myeloid leukemia (aml)
ejection fraction
graft versus host disease
gilbert's syndrome
bone marrow procedure
  • 9 views
  • 15 Jul, 2022
  • 1 location
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

The purpose of this study is to evaluate the safety and tolerability and to determine the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD) of ASP7517. This study will also evaluate the clinical response of ASP7517 as well as other measures of anticancer activity of ASP7517.

refractory acute myeloid leukemia (aml)
remission
induction chemotherapy
secondary acute myeloid leukemia
blast cells
  • 10 views
  • 25 Jul, 2022
  • 22 locations
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

This study is a phase I/II study of TJ011133 as Monotherapy and in Combination with Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). This study

azacitidine
acute promyelocytic leukemia
refractory acute myeloid leukemia (aml)
induction chemotherapy
white blood cell count
  • 5 views
  • 29 Jul, 2022
  • 25 locations
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

patients with MDS (Myelodysplastic Syndrome) and mutated IDH1 patients will be treated with AG120 (IDH1 inhibitor)

blast cells
azacitidine
ejection fraction
cytopenia
blood transfusion
  • 7 views
  • 08 Aug, 2022
  • 6 locations
Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

While chimeric antigen receptor T-cell (CAR T-cell) therapy produces impressive response rates in heavily pre-treated patients, early loss of response remains a barrier. One potential mechanism of relapse is limited CAR T-cell persistence. Pre-clinical research shows that PI3K inhibition represents an intriguing mechanism for increasing CAR T-cell persistence that is …

leukemia
  • 0 views
  • 27 Jul, 2022
  • 1 location
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine

The purpose of this study is to evaluate the safety of progressively substituting day +3 and +4 post-transplant cyclophosphamide (PT-CY) with post-transplant bendamustine (PT-BEN) in myeloablative (MAC) haploidentical hematopoietic cell transplantation (HHCT) for patients with hematological malignancies. The goal of the Phase 1 component of the study is to evaluate …

lymphoid leukemia
cancer
burkitt's lymphoma
high risk myelodysplastic syndrome
remission
  • 31 views
  • 03 Jun, 2022
  • 1 location
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

This phase I/II trial studies the side effects and how well cladribine, idarubicin, cytarabine, and quizartinib work in treating patients with acute myeloid leukemia or high-risk myelodysplastic

cancer
ejection fraction
cytarabine
blast cells
hematopoietic growth factors
  • 2 views
  • 26 May, 2022
  • 1 location
Zanubrutinib + Venetoclax in CLL/SLL

This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic

cancer
acalabrutinib
platelet count
venetoclax
chronic lymphocytic leukemia
  • 0 views
  • 19 Apr, 2022
  • 2 locations